Scarica l'app Stockscreener
18.81
0.37%
-0.07
Pre-mercato:
19.15
0.34
+1.81%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$18.88
Aprire:
$18.72
Volume 24 ore:
891.22K
Relative Volume:
0.90
Capitalizzazione di mercato:
$1.59B
Reddito:
$123.67M
Utile/perdita netta:
$-38.63M
Rapporto P/E:
-30.49
EPS:
-0.617
Flusso di cassa netto:
$-27.50M
1 W Prestazione:
+3.64%
1M Prestazione:
-10.34%
6M Prestazione:
+32.28%
1 anno Prestazione:
+364.44%
Intervallo 1D:
$18.45
$19.79
Intervallo di 1 settimana:
$17.43
$19.79
Portata 52W:
$3.90
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
18.81 | 1.59B | 123.67M | -38.63M | -27.50M | -0.617 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa Therapeutics director sells $180,100 of Glue shares By Investing.com - Investing.com Canada
Monte Rosa Therapeutics director sells $180,100 of Glue shares - Investing.com
Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development - Traders Union
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Monte Rosa lines up TD Cowen and Jefferies investor talks - Stock Titan
Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Monte Rosa Therapeutics (GLUE) — TCG/Chen Yu report 5.5% holding - Stock Titan
[SCHEDULE 13G/A] Monte Rosa Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
BVF Group (GLUE) entities report up to 5.09M shares, 6.3% total - Stock Titan
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar - Traders Union
Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention - Yahoo Finance
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics 1Q Research and Development Expenses $44.1M >GLUE - Moomoo
10 Health Care Stocks Whale Activity In Today's Session - Sahm
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts - ChartMill
MONTE ROSA THERAPEUTICS ($GLUE) Releases Q1 2026 Earnings - Quiver Quantitative
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Monte Rosa Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M - marketscreener.com
Monte Rosa Therapeutics 1Q 2026: Revenue $4.21M, EPS $(0.45) — 10-Q Summary - TradingView
Monte Rosa (NASDAQ: GLUE) swings to Q1 loss but extends cash runway into 2029 - Stock Titan
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, Vs. FactSet Est of $11.4M - Moomoo
Biotech Monte Rosa says its $671M cash pile funds operations into 2029 - Stock Titan
Monte Rosa (NASDAQ: GLUE) swings to Q1 2026 loss, builds cash runway into 2029 - Stock Titan
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? By Investing.com - Investing.com Australia
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? - Investing.com India
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Planned Monte Rosa (GLUE) CEO share sale under Rule 10b5-1 - Stock Titan
GLUE Forecast, Price Target & Analyst Ratings | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com
Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 103.45 Million in Common Stocks - Moomoo
Monte Rosa Therapeutics (GLUE) Form 144: RSU 21,865; Markus Warmuth sales listed - Stock Titan
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2% - MarketBeat
Monte Rosa Therapeutics | DEF 14A: Definitive information statements - Moomoo
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):